Abstract:10.1038/aps.2013.109 S2.1 The anti-fibrotic effect of thymoquinone on thioacetamide-induced mouse hepatic fibrosis Ting BAI, Yong YANG, Li-hua LIAN, Yan-ling WU, Shuang JIANG, Hui-xing ZHENG, Xin LI, Jin-bin LI, You-li YAO, Ji-xing NAN*. Key Laboratory for Natural Resource of Changbai Mountain & Functional Molecules, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China *To whom correspondence should be addressed. E-mail: jxnanybu@gmail.com Aim: Thymoquinone (TQ) is the main active ingredient from the seeds of Nigella sativa Linn, which has been traditionally used in the Middle East and Southeast Asian countries to treat ailments including asthma, bronchitis, rheumatism, cancer and related inflammatory diseases. In the present study, we investigate the antifibrotic effect and the potential mechanisms of action of TQ against hepatic fibrosis in vivo. Methods: Liver fibrosis was induced by intraperitoneal injections of thioacetamide (TAA, 200 mg/kg) three weekly for 5 weeks in male kunming mice. The administration of TQ (20, 40 mg/kg) was started following TAA injections and was continued for 5 weeks to evaluate the protective effects by hematoxylin and eosin (H&E) staining and Masson staining. The protein and mRNA extracted from liver tissue were analyzed by Western blotting analysis and Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR). Results: Our data demonstrated that treated with TQ obviously improved tissue damage compared with TAA-only group, in that less inflammatory cell infiltration was observed in H&E and Masson staining results. TQ demonstrated great efficacy in curing hepatic fibrosis via attenuating the TAA-mediated α-smooth muscle actin (α-SMA) and Collagen-I. TQ significantly inhibited the expression of toll-like receptor 4 (TLR4), tissue inhibitor of metalloproteinase-1 (TIMP-1) and α-SMA by Western blotting analysis and RT-PCR. TQ also significantly inhibited phosphatidylinositol 3-kinase (PI3K) phosphorylation and the phosphorylation adenosine monophosphateactivated protein kinase (AMPK) and liver kinase B (LKB)-1. Furthermore, TQ significantly decreased the expression of interleukin (IL)-1b and IL-18 in TAAinduced mouse hepatic fibrosis. Conclusion: The potential anti-fibrosis mechanism of TQ might be associated with the depression of α-SMA and Collagen-I relating with hepatic fibrosis, down-regulating the accompanying inflammatory response in hepatic fibrosis. TQ suppressed PI3K signaling and activated LKB-1 signaling in TAA-induced mouse hepatic fibrosis, suggesting that TQ may be a potential candidate for the therapy of hepatic fibrosis.

Dihydromyricetin Reverses Thioacetamide-Induced Liver Fibrosis Through Inhibiting NF-κB-Mediated Inflammation and TGF-β1-Regulated of PI3K/Akt Signaling Pathway

Dihydromyricetin Reverses Thioacetamide-Induced Liver Fibrosis Through Inhibiting NF-κB-Mediated Inflammation and TGF-β1-Regulated of PI3K/Akt Signaling Pathway

Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Study on Dihydromyricetin Improving Aflatoxin Induced Liver Injury Based on Network Pharmacology and Molecular Docking

Dihydromyricetin Attenuates Streptozotocin‐induced Liver Injury and Inflammation in Rats Via Regulation of NF‐κB and AMPK Signaling Pathway

Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling

Dihydromyricetin Alleviates Acetaminophen-Induced Liver Injury Via the Regulation of Transformation, Lipid Homeostasis, Cell Death and Regeneration.

The anti-fibrotic effect of thymoquinone on thioacetamide-induced mouse hepatic fibrosis

Hepatic Stellate Cell- and Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis

Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease

Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway

Tao-Hong-Si-Wu-Tang improves thioacetamide-induced liver fibrosis by reversing ACSL4-mediated lipid accumulation and promoting mitophagy

Vitamin D Ameliorates the Hepatic Oxidative Damage and Fibrotic Effect Caused by Thioacetamide in Rats

Hepatoprotective Effect of Picroside I on Thioacetamide-Induced Hepatic Fibrosis Determined by Metabolomic and Proteomic Analyses

Dihydromyricetin Alleviates Nonalcoholic Fatty Liver Disease and Its Associated Metabolic Syndrome by Inhibiting Endoplasmic Reticulum Stress in LDLR−/− Mice Fed with a High-Fat and High-Fructose Diet

Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation

Adiponectin-Derived Active Peptide Adp355 Exerts Anti-Inflammatory and Anti-Fibrotic Activities in Thioacetamide-Induced Liver Injury

Abscisic Acid Ameliorates Oxidative Stress, Inflammation, and Apoptosis in Thioacetamide-Induced Hepatic Fibrosis by Regulating the NF-кB Signaling Pathway in Mice.

Thymoquinone Alleviates Thioacetamide-Induced Hepatic Fibrosis and Inflammation by Activating Lkb1-Ampk Signaling Pathway in Mice

Dihydromyricetin ameliorates diabetic renal fibrosis via regulating SphK1 to suppress the activation of NF-κB pathway